| Role |
Name |
Disclosure |
Details |
| Author | Sandra L Friedman, MD, MPH, Assistant Professor of Pediatrics, Harvard University Medical School; Director of Pediatrics, LEND/UCEDD, Department of Medicine, Division of General Pediatrics, Children's Hospital of Boston | Nothing to disclose | Details | | Coauthor | Kerim M Munir, MD, MPH, DSc, Director of Psychiatry, LEND/UCEDD, Division of General Pediatrics, Dir of Mental Health and Developmental Disabilities (MHDD) Training Prog, Children's Hospital Boston | None | Details | | Coauthor | Marilyn T Erickson, PhD, Professor Emeritus, Department of Psychology, Virginia Commonwealth University | Nothing to disclose | Details | | Medical Editor | Chet Johnson, MD, Medical Director, Child Development Unit, Department of Pediatrics, Professor, University of Kansas Medical Center | Nothing to disclose | Details | | Pharmacy Editor | Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc | Pfizer Inc Avanir Pharma | Details | | CME Editor | Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine | Baxter Pfizer | Details | | Chief Editor | Caroly Pataki, MD, Professor of Clinical Psychiatry, Department of Psychiatry and Biobehavioral Sciences, Division Chair of Child and Adolescent Psychiatry, Director of Training, Child and Adolescent Psychiatry Residency Program, University of Southern California Keck School of Medicine | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Marilyn T Erickson, Coauthor |
The contributor discloses no conflict of interest. |
|